An adaptive power prior for sequential clinical trials – Application to bridging studies

During drug evaluation trials, information from clinical trials previously conducted on another population, indications or schedules may be available. In these cases, it might be desirable to share information by efficiently using the available resources. In this work, we developed an adaptive power prior with a commensurability parameter for using historical or external information. It allows, at each stage, full borrowing when the data are not in conflict, no borrowing when the data are in conflict or “tuned” borrowing when the data are in between. We propose to apply our adaptive power prior method to bridging studies between Caucasians and Asians, and we focus on the sequential adaptive allocation design, although other design settings can be used. We weight the prior information in two steps: the effective sample size approach is used to set the maximum desirable amount of information to be shared from historical data at each step of the trial; then, in a sort of Empirical Bayes approach, a commensurability parameter is chosen using a measure of distribution distance. This approach avoids elicitation and computational issues regarding the usual Empirical Bayes approach. We propose several versions of our method, and we conducted an extensive simulation study evaluating the robustness and sensitivity to prior choices.

[1]  Ying Yuan,et al.  Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials , 2009 .

[2]  Kit C B Roes,et al.  Dynamic borrowing through empirical power priors that control type I error , 2018, Biometrics.

[3]  P. Müller,et al.  Determining the Effective Sample Size of a Parametric Prior , 2008, Biometrics.

[4]  Adrian E. Raftery,et al.  Bayesian model averaging: a tutorial (with comments by M. Clyde, David Draper and E. I. George, and a rejoinder by the authors , 1999 .

[5]  S J Pocock,et al.  The combination of randomized and historical controls in clinical trials. , 1976, Journal of chronic diseases.

[6]  Joseph G Ibrahim,et al.  The power prior: theory and applications , 2015, Statistics in medicine.

[7]  Bradley P Carlin,et al.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. , 2012, Bayesian analysis.

[8]  Adam Himes,et al.  Incorporation of stochastic engineering models as prior information in Bayesian medical device trials , 2017, Journal of biopharmaceutical statistics.

[9]  Tim Friede,et al.  Dynamically borrowing strength from another study through shrinkage estimation , 2018, Statistical methods in medical research.

[10]  Sarah Zohar,et al.  An approach to meta‐analysis of dose‐finding studies , 2011, Statistics in medicine.

[11]  Joseph G Ibrahim,et al.  A practical Bayesian adaptive design incorporating data from historical controls , 2018, Statistics in medicine.

[12]  S. Morita,et al.  Incorporating Historical Data in Bayesian Phase I Trial Design: The Caucasian-to-Asian Toxicity Tolerability Problem , 2015, Therapeutic innovation & regulatory science.

[13]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[14]  B. Reigner,et al.  Pharmacokinetics of capecitabine (Xeloda) in Japanese and Caucasian patients with breast cancer , 2003, Cancer Chemotherapy and Pharmacology.

[15]  L Zhang,et al.  The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.

[16]  Satoshi Morita,et al.  Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies , 2016, Statistical methods in medical research.

[17]  Ying Yuan,et al.  Bridging continual reassessment method for phase I clinical trials in different ethnic populations , 2015, Statistics in medicine.

[18]  Leonhard Held,et al.  Adaptive power priors with empirical Bayes for clinical trials , 2017, Pharmaceutical statistics.

[19]  Anthony O'Hagan,et al.  Robust meta‐analytic‐predictive priors in clinical trials with historical control information , 2014, Biometrics.

[20]  Ying Kuen Cheung,et al.  Dose Finding by the Continual Reassessment Method , 2011 .

[21]  Bradley P Carlin,et al.  Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials , 2011, Biometrics.

[22]  Sarah Zohar,et al.  Using the continual reassessment method to estimate the minimum effective dose in phase II dose-finding studies: a case study , 2013, Clinical trials.

[23]  Yvette van Norden,et al.  Including historical data in the analysis of clinical trials: Is it worth the effort? , 2017, Statistical methods in medical research.

[24]  Satoshi Morita,et al.  Prior Effective Sample Size in Conditionally Independent Hierarchical Models. , 2012, Bayesian analysis.

[25]  Dario Gregori,et al.  Planning a Bayesian early‐phase phase I/II study for human vaccines in HER2 carcinomas , 2011, Pharmaceutical statistics.

[26]  J. Ibrahim,et al.  Power prior distributions for regression models , 2000 .

[27]  H. Maeda,et al.  Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries , 2014, Investigational New Drugs.

[28]  Alexia Iasonos,et al.  Bridging Solutions in Dose-Finding Problems , 2014, Statistics in biopharmaceutical research.

[29]  G. Liu A dynamic power prior for borrowing historical data in noninferiority trials with binary endpoint , 2018, Pharmaceutical statistics.

[30]  J. Bernardo The Concept of Exchangeability and its Applications , 2001 .

[31]  Ying Yuan,et al.  A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. , 2017, Journal of the Royal Statistical Society. Series C, Applied statistics.

[32]  Satoshi Morita,et al.  Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics , 2010, Statistics in biosciences.

[33]  Chikayuki Naito,et al.  Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .

[34]  Michael Branson,et al.  A note on the power prior , 2009, Statistics in medicine.